# Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)

> **NCT06297603** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Eli Lilly and Company** · enrollment: 320 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Retatrutide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06297603
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-03-15
- **Primary completion:** 2026-10
- **Final completion:** 2026-11
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2025-12-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06297603

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06297603, "Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT06297603. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*